Literature DB >> 18598196

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Bali Pulendran1, Joseph Miller, Troy D Querec, Rama Akondy, Nelson Moseley, Oscar Laur, John Glidewell, Nathan Monson, Tuofu Zhu, Haiying Zhu, Sylvija Staprans, David Lee, Margo A Brinton, Andrey A Perelygin, Claudia Vellozzi, Philip Brachman, Susan Lalor, Dirk Teuwen, Rachel B Eidex, Marty Cetron, Frances Priddy, Carlos del Rio, John Altman, Rafi Ahmed.   

Abstract

BACKGROUND: The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most effective vaccines. Despite its excellent safety record, some cases of viscerotropic adverse events develop, which are sometimes fatal. The mechanisms underlying such events remain a mystery. Here, we present an analysis of the immunologic and genetic factors driving disease in a 64-year-old male who developed viscerotropic symptoms.
METHODS: We obtained clinical, serologic, virologic, immunologic and genetic data on this case patient.
RESULTS: Viral RNA was detected in the blood 33 days after vaccination, in contrast to the expected clearance of virus by day 7 after vaccination in healthy vaccinees. Vaccination induced robust antigen-specific T and B cell responses, which suggested that persistent virus was not due to adaptive immunity of suboptimal magnitude. The genes encoding OAS1, OAS2, TLR3, and DC-SIGN, which mediate antiviral innate immunity, were wild type. However, there were heterozygous genetic polymorphisms in chemokine receptor CCR5, and its ligand RANTES, which influence the migration of effector T cells and CD14+CD16bright monocytes to tissues. Consistent with this, there was a 200-fold increase in the number of CD14+CD16bright monocytes in the blood during viremia and even several months after virus clearance.
CONCLUSION: In this patient, viscerotropic disease was not due to the impaired magnitude of adaptive immunity but instead to anomalies in the innate immune system and a possible disruption of the CCR5-RANTES axis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598196      PMCID: PMC3734802          DOI: 10.1086/590187

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

Authors:  Scott Kitchener
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

2.  Overexpression of RANTES using a recombinant adenovirus vector induces the tissue-directed recruitment of monocytes to the lung.

Authors:  T A Braciak; K Bacon; Z Xing; D J Torry; F L Graham; T J Schall; C D Richards; K Croitoru; J Gauldie
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

3.  Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES.

Authors:  R G Nickel; V Casolaro; U Wahn; K Beyer; K C Barnes; B S Plunkett; L R Freidhoff; C Sengler; J R Plitt; R P Schleimer; L Caraballo; R P Naidu; P N Levett; T H Beaty; S K Huang
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.

Authors:  M Murai; H Yoneyama; A Harada; Z Yi; C Vestergaard; B Guo; K Suzuki; H Asakura; K Matsushima
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 5.  New developments in flavivirus vaccines with special attention to yellow fever.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Thomas P Monath
Journal:  Curr Opin Infect Dis       Date:  2005-10       Impact factor: 4.915

6.  Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.

Authors:  Florian Hladik; Huanliang Liu; Emily Speelmon; Devon Livingston-Rosanoff; Sean Wilson; Polachai Sakchalathorn; Yon Hwangbo; Benjamin Greene; Tuofu Zhu; M Juliana McElrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Authors:  Alena Y Khromava; Rachel Barwick Eidex; Leisa H Weld; Katrin S Kohl; Robert D Bradshaw; Robert T Chen; Martin S Cetron
Journal:  Vaccine       Date:  2005-05-09       Impact factor: 3.641

8.  Enzymatic activity of 2'-5'-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization of the protein.

Authors:  A Ghosh; S N Sarkar; W Guo; S Bandyopadhyay; G C Sen
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

9.  Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1.

Authors:  Huanliang Liu; Yon Hwangbo; Sarah Holte; Jean Lee; Chunhui Wang; Nicole Kaupp; Haiying Zhu; Connie Celum; Lawrence Corey; M Juliana McElrath; Tuofu Zhu
Journal:  J Infect Dis       Date:  2004-08-02       Impact factor: 5.226

10.  Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis.

Authors:  M Frankenberger; T Sternsdorf; H Pechumer; A Pforte; H W Ziegler-Heitbrock
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

View more
  52 in total

1.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

2.  Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data.

Authors:  Stephen J Seligman; Joel E Cohen; Yuval Itan; Jean-Laurent Casanova; John C Pezzullo
Journal:  Am J Trop Med Hyg       Date:  2014-01-06       Impact factor: 2.345

Review 3.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

Review 4.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

5.  Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?

Authors:  Yoav Keynan; Jennifer Juno; Ken Kasper; Ethan Rubinstein; Keith R Fowke
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

6.  Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.

Authors:  Rama S Akondy; Philip L F Johnson; Helder I Nakaya; Srilatha Edupuganti; Mark J Mulligan; Benton Lawson; Joseph D Miller; Bali Pulendran; Rustom Antia; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

7.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

Review 8.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06

9.  Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.

Authors:  Maria del P Martin; Shaguna Seth; Dimitrios G Koutsonanos; Joshy Jacob; Richard W Compans; Ioanna Skountzou
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.